Efficacy and safety of rituximab biosimilar in refractory lupus.

Nantakarn PongtarakulpanitPrapaporn PisitkunPintip Ngamjanyaporn

Published in: Lupus science & medicine (2021)

Rituximab biosimilar is associated with improvement in active organ involvement in patients with refractory SLE. Infection occurred early after rituximab biosimilar infusion.

Keyphrases

diffuse large b cell lymphoma
systemic lupus erythematosus
chronic lymphocytic leukemia
hodgkin lymphoma
disease activity
low dose
rheumatoid arthritis